48-hour access to this article

Background

Dopamine agonists (DAs) are the main treatment for patients with hyperprolactinemia and prolactinomas. Recently, an increasing number of reports emphasized DAs’ psychological side effects, either de novo or as exacerbations of prior psychiatric disease.

Methods

Review of prospective and retrospective studies (PubMed 1976, September 2018) evaluating the psychological profile of DA-treated patients with hyperprolactinemia and prolactinomas. Case series and case reports of psychiatric complications were also reviewed.

Results

Most studies were cross-sectional and had a control group of healthy volunteers or patients with nonfunctioning pituitary adenomas. There were few prospective studies, with/without control group, that included small numbers of patients. Compared with controls, patients with hyperprolactinemia generally had worse quality of life, anxiety, depression and certain personality traits. Patients receiving DAs had higher impulsivity scores than normoprolactinemic controls. Impulse control disorders (ICDs) were reported in both genders, with hypersexuality mostly in men. Multiple ICDs were sometimes reported in the same patient, usually reversible after DA discontinuation. In case reports, DA therapy was temporally associated with severe depression, manic episodes or psychosis, which improved after discontinuation and administration of psychiatric medications. Gender type of DA, dose and duration of therapy did not correlate with occurrence of psychiatric pathology.

Conclusion

Patients with hyperprolactinemia receiving DAs may develop changes in mood and behavior regardless of prior psychiatric history. Increased awareness for ICDs, depression, mania and other types of psychosis is needed by all physicians who prescribe DAs. Larger prospective controlled clinical studies are needed to delineate prevalence, risk stratification and management.

AthanasouliaAPSieversCIsingMBrockhausACYassouridisAStallaGKUhrM.Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. European Journal of Endocrinology2012167327–335. (https://doi.org/10.1530/EJE-12-0198)

KarsMvan der KlaauwAAOnsteinCSPereiraAMRomijnJA.Quality of life is decreased in female patients treated for microprolactinoma. European Journal of Endocrinology2007157133–139. (https://doi.org/10.1530/EJE-07-0259)

Athanasoulia-KasparAPPoppKHStallaGK.Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. Endocrine Connections20187R88–R94. (https://doi.org/10.1530/EC-18-0030)

DavieM.Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. Journal of Neuropsychiatry and Clinical Neurosciences200719473–474. (https://doi.org/10.1176/jnp.2007.19.4.473)

ThondamSKAlusiSO'DriscollKGilkesCECuthbertsonDJDaousiC.Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clinical Neuropharmacology201336170–172. (https://doi.org/10.1097/WNF.0b013e31829fc165)

De SousaSMChapmanIMFalhammarHTorpyDJ.Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine201755618–624. (https://doi.org/10.1007/s12020-016-1088-1)

BulwerCConnRShankarAFerrauFKapurSEderiesAKorbonitsMSpoudeasHA.Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clinical Endocrinology201786862–864. (https://doi.org/10.1111/cen.13339)

RoveraCCremaschiLThanjuAFiorentiniAMauriMCSeratiMLindenmayerJPAltamuraAC.Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report. Asian Journal of Psychiatry20162294–95. (https://doi.org/10.1016/j.ajp.2016.05.010)

FreemanBLevyWGormanJM.Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. Journal of Psychiatric Practice200713120–124. (https://doi.org/10.1097/01.pra.0000265771.47153.a0)

HofferZSRothRLMathewsM.Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics200950317–324. (https://doi.org/10.1176/appi.psy.50.4.317)

BroekhofRGosselinkMJPijlHGiltayEJ.The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. General Hospital Psychiatry201234209.e1–209.e3.

Santos AndradeEHPanPMda SilvaPFGadelhaA.New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literature. Case Reports in Medicine20102010573252.